A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Retia Medical Reports Multi-Beat Analysis Algorithm New Study Further Confirms Superior Accuracy in Comparison to a Competing Option

Retia Medical reported today the publication of a new study that further confirms the superior accuracy of its Multi-Beat Analysis (MBA™) algorithm in comparison to a competing option. The study, published on July 10th in BMC Anesthesiology (https://bmcanesthesiol.biomedcentral.com/track/pdf/10.1186/s12871-021-01415-5.pdf) compared the accuracy of two cardiac output monitors, the Retia Argos and the Edwards Lifesciences FloTrac across 58 patients undergoing off-pump coronary artery bypass surgery, yielding 572 sets of cardiac output measurements from each device.

The measurements from each monitor were compared to the reference, thermodilution measurements from an invasive, pulmonary artery catheter (PAC). Both the absolute accuracy (error = 1.16 L/min) and the trending accuracy (87%) of the Retia monitor were better than the Edwards monitor (1.54 L/min and 72%, respectively). These results were statistically significant (p < 0.02).

“The Argos device is superior to other non-invasive cardiac output monitors on the market and remains precise across a myriad of conditions.  It quite simply is a leap forward in technology,” said Dr. Benjamin Kohl, Vice Chair of Critical Care at Thomas Jefferson University. Dr. Kohl continued “Retia has developed a superior algorithm that enables rapid and intelligent decision-making in a single device that does not require purchase of any disposable equipment.”

Off-pump coronary artery bypass graft surgery is a challenging cardiac surgery where patients experience significant hemodynamic variations. Other studies have shown that the rates of acute kidney injuries (AKIs) after cardiac surgery can range from 20% to 40% and that using hemodynamic monitors to guide care of these patients can help reduce the rates of these complications. Providing clinicians a more accurate picture of the patient’s status may potentially help them further improve patient outcomes.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy